Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C2H4NO2.Mg |
Molecular Weight | 172.4223 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Mg++].NCC([O-])=O.NCC([O-])=O
InChI
InChIKey=AACACXATQSKRQG-UHFFFAOYSA-L
InChI=1S/2C2H5NO2.Mg/c2*3-1-2(4)5;/h2*1,3H2,(H,4,5);/q;;+2/p-2
DescriptionSources: http://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243https://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://www.db-pharma.com/anglais/49.pdfhttp://www.sciencedirect.com/science/article/pii/004484868990080Xhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttps://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640DOI: 10.2903/j.efsa.2008.883http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfdoi: 10.1081/SCC-120022479https://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1https://www.drugs.com/ppa/magnesium-chloride.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9https://www.drugs.com/dosage/magnesium-lactate.htmlhttp://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/351265Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9873215 | http://discovery.ucl.ac.uk/1336882/1/1336882.pdf
Sources: http://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243https://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://www.db-pharma.com/anglais/49.pdfhttp://www.sciencedirect.com/science/article/pii/004484868990080Xhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttps://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640DOI: 10.2903/j.efsa.2008.883http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfdoi: 10.1081/SCC-120022479https://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1https://www.drugs.com/ppa/magnesium-chloride.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9https://www.drugs.com/dosage/magnesium-lactate.htmlhttp://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/351265
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9873215 | http://discovery.ucl.ac.uk/1336882/1/1336882.pdf
Struvite, a crystalline substance first identified in the 18th century, is composed of magnesium ammonium
phosphate. Struvite urinary stones are also known as ‘infection stones’, and account for 15%-20% of all urinary stones. Bacterial urease, usually from a Proteus species, is responsible for the chemical changes in urine which result in struvite formation.
CNS Activity
Sources: DOI: 10.1002/0471238961.0218151310010311.a02Vink, R., Mihai Nechifor, M. (2011) 'Magnesium in the Central Nervous System', p.139 Retrieved from https://books.google.ru/books?id=GW0oExaZ7hQChttps://www.drugs.com/mtm/magnesium-lactate.html | https://www.ncbi.nlm.nih.gov/pubmed/27792736 | https://www.ncbi.nlm.nih.gov/pubmed/7669506
Curator's Comment: Magnesium Chloride
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/351265
Curator's Comment: Ulex, a Swedish geologist, is generally credited with introduction of the term struvite in1845
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0001508 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12225296 |
|||
Target ID: GO:0010960 |
|||
Target ID: GO:0033609 |
|||
Target ID: GO:0010960 |
|||
Target ID: P05109 Gene ID: 6279.0 Gene Symbol: S100A8 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8061680 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Preventing | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Primary | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Diagnostic | ColPrep Kit Approved UseINDICATIONS AND USAGE
ColPrep Kit is indicated for cleansing of the colon as a preparation for colonoscopy in adults Launch Date2016 |
|||
Primary | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Curative | MagMin Approved UseMagnesium aspartate (MagMin) is indicated for patients with documented hypomagnesaemia. |
|||
Curative | DELBIASE Approved UseUnknown |
|||
Primary | DELBIASE Approved UseUnknown |
|||
Primary | DELBIASE Approved UseUnknown |
|||
Curative | Magnesium Chloride Approved UseMagnesium Chloride injection is indicated as an electrolyte replenisher in magnesium deficiencies |
|||
Palliative | Magnesium Chloride Approved UseUnknown |
|||
Palliative | Magnesium Chloride Approved UseUnknown |
|||
Primary | EPIMAG Approved UseMagnesium citrate is indicated in cases of oxaluria, to prevent recurrence of calcium oxalate kidney stones. |
|||
Primary | EPIMAG Approved UseUsed to relief of occasional constipation (irregularity). |
|||
Curative | Magnesium Citrate Approved UseMagnesium citrate is indicated to supports magnesium nutritional adequacy. |
|||
Curative | Unknown Approved UseMagnesium lactate is a naturally occurring mineral that is needed in the body to support the function of the heart, nervous system, and digestive system. Magnesium lactate is used as a mineral supplement to treat magnesium deficiency. |
PubMed
Title | Date | PubMed |
---|---|---|
Evidence for separate peptide sequences related to the lipolytic and magnesium-accumulating activities of ACTH. Analogy with adrenergic receptors. | 1977 Apr |
|
[Magnesium--an alternative in treatment resistant tachyarrhythmias]. | 1977 May 30 |
|
Metal: ATP characteristics of insulin- and epidermal growth factor-stimulated phosphorylation in detergent extracts of rat liver plasma membranes. | 1986 Sep |
|
[Arrhythmogenic effect of flecainide--treatment with i.v. magnesium]. | 1989 Sep |
|
Cocaine-induced cerebral vascular damage can be ameliorated by Mg2+ in rat brain. | 1990 Feb 5 |
|
Role of magnesium in cardiac tachyarrhythmias. | 1990 Jun 19 |
|
Modulation of mu, delta and kappa opioid receptors in rat brain by metal ions and histidine. | 1990 May |
|
Sotalol-induced torsade de pointes: management with magnesium infusion. | 1992 Apr |
|
[Heart rate disorders in potassium and magnesium deficiency]. | 1992 Sep 7 |
|
['Cardiac ballet' with and without amiodarone]. | 1993 Jan 13 |
|
Effects of felbamate on muscarinic and metabotropic-glutamate agonist-mediated responses and magnesium-free or 4-aminopyridine-induced epileptiform activity in guinea pig olfactory cortex neurons in vitro. | 1996 Jun |
|
Familial hypomagnesemia--hypercalciuria and pseudotumor cerebri. | 2001 |
|
Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed. | 2002 Jul |
|
Vasodilator agents protect against indinavir nephrotoxicity. | 2003 Aug |
|
Cell-associated magnesium and QT dispersion in hemodialysis patients. | 2003 Jan |
|
Effects of antiepileptic drugs on refractory seizures in the intact immature corticohippocampal formation in vitro. | 2003 Nov |
|
Enhancement of endotoxin-induced vascular hyporeactivity to phenylephrine in the thoracic aortas of Mg-deficient rats ex vivo. | 2003 Oct 10 |
|
Elevated levels of ferrimagnetic metals in foodchains supporting the Guam cluster of neurodegeneration: do metal nucleated crystal contaminants [corrected] evoke magnetic fields that initiate the progressive pathogenesis of neurodegeneration? | 2004 |
|
The effect of cations on the amidase activity of human tissue kallikrein: 1-linear competitive inhibition by sodium, potassium, calcium and magnesium. 2-linear mixed inhibition by aluminium. | 2004 Aug |
|
Ablation of calcitonin/calcitonin gene-related peptide-alpha impairs fetal magnesium but not calcium homeostasis. | 2004 Aug |
|
Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. | 2004 Aug 18 |
|
Low maternal dietary intakes of iron, magnesium, and niacin are associated with spina bifida in the offspring. | 2004 Jun |
|
Magnesium influence on morphine--induced pharmacodependence in rats. | 2004 Mar |
|
A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium. | 2004 May |
|
In vitro application of endotoxin to thoracic aortas from magnesium-deficient rats enhances vascular hyporeactivity to phenylephrine. | 2004 Oct |
|
Major and trace elements in whole blood of phlebotomized patients with porphyria cutanea tarda. | 2005 |
|
Prevention of succinylcholine-induced fasciculation and myalgia: a meta-analysis of randomized trials. | 2005 Oct |
|
Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. | 2005 Oct |
|
Conformational changes in sarcoplasmic reticulum Ca(2+)-ATPase mutants: effect of mutations either at Ca(2+)-binding site II or at tryptophan 552 in the cytosolic domain. | 2006 Apr 25 |
|
Structure of pyrimidine 5'-nucleotidase type 1. Insight into mechanism of action and inhibition during lead poisoning. | 2006 Jul 21 |
|
Kinetic properties of chimeric class I aldehyde dehydrogenases for retinal isomers. | 2006 Oct |
|
Divalent-metal-dependent nucleolytic activity of Cu, Zn superoxide dismutase. | 2006 Oct |
|
Magnesium attenuates isoproterenol-induced acute cardiac dysfunction and beta-adrenergic desensitization. | 2007 Mar |
|
Characterization and distribution of the selected metals in the scalp hair of cancer patients in comparison with normal donors. | 2007 Sep |
|
The relation of magnesium and calcium intakes and a genetic polymorphism in the magnesium transporter to colorectal neoplasia risk. | 2007 Sep |
|
Treatment of migraine with prophylactic drugs. | 2008 Oct |
|
Differential binding of inorganic particles to MARCO. | 2009 Jan |
|
The loop connecting metal-binding domains 3 and 4 of ATP7B is a target of a kinase-mediated phosphorylation. | 2009 Jun 23 |
|
Hair tissue mineral analysis and metabolic syndrome. | 2009 Sep |
|
Differential effects of divalent manganese and magnesium on the kinase activity of leucine-rich repeat kinase 2 (LRRK2). | 2010 Apr 13 |
|
Involvement of transient receptor potential melastatin-related 7 (TRPM7) channels in cadmium uptake and cytotoxicity in MC3T3-E1 osteoblasts. | 2010 Dec 15 |
|
Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes. | 2011 Feb |
|
Mechanically enforced bond dissociation reports synergistic influence of Mn2+ and Mg2+ on the interaction between integrin α7β1 and invasin. | 2011 Jul-Aug |
|
Hypoxia induces an increase in intracellular magnesium via transient receptor potential melastatin 7 (TRPM7) channels in rat hippocampal neurons in vitro. | 2011 Jun 10 |
|
Increased zinc and manganese in parallel with neurodegeneration, synaptic protein changes and activation of Akt/GSK3 signaling in ovine CLN6 neuronal ceroid lipofuscinosis. | 2013 |
|
Warfarin accelerates ectopic mineralization in Abcc6(-/-) mice: clinical relevance to pseudoxanthoma elasticum. | 2013 Apr |
|
Ofloxacin induces apoptosis via β1 integrin-EGFR-Rac1-Nox2 pathway in microencapsulated chondrocytes. | 2013 Feb 15 |
|
Fluorescence lifetime analysis and effect of magnesium ions on binding of NADH to human aldehyde dehydrogenase 1. | 2013 Feb 25 |
|
Catalytic contribution of threonine 244 in human ALDH2. | 2013 Feb 25 |
|
Altered biometal homeostasis is associated with CLN6 mRNA loss in mouse neuronal ceroid lipofuscinosis. | 2013 Jun 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27995243
Curator's Comment: Rats: MgF2 dissolved in acetic acid (Mg=0.08 mM, F=0.084 mM) was delivered in the aerosol form
https://www.ncbi.nlm.nih.gov/pubmed/20647692
Murine osteomyelitis model: medical pure titanium plates in size of 10 mm × 10 mm × 1 mm
were used for the deposition of Magnesium Fluoride (MgF2) film.
Route of Administration:
Topical
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 331.11
Created by
admin on Fri Dec 15 15:51:00 GMT 2023 , Edited by admin on Fri Dec 15 15:51:00 GMT 2023
|
||
|
CFR |
21 CFR 331.15
Created by
admin on Fri Dec 15 15:51:00 GMT 2023 , Edited by admin on Fri Dec 15 15:51:00 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C091418
Created by
admin on Fri Dec 15 15:51:00 GMT 2023 , Edited by admin on Fri Dec 15 15:51:00 GMT 2023
|
PRIMARY | |||
|
IFN18A4Y6B
Created by
admin on Fri Dec 15 15:51:00 GMT 2023 , Edited by admin on Fri Dec 15 15:51:00 GMT 2023
|
PRIMARY | |||
|
C76082
Created by
admin on Fri Dec 15 15:51:00 GMT 2023 , Edited by admin on Fri Dec 15 15:51:00 GMT 2023
|
PRIMARY | |||
|
476818
Created by
admin on Fri Dec 15 15:51:00 GMT 2023 , Edited by admin on Fri Dec 15 15:51:00 GMT 2023
|
PRIMARY | RxNorm | ||
|
100000086503
Created by
admin on Fri Dec 15 15:51:00 GMT 2023 , Edited by admin on Fri Dec 15 15:51:00 GMT 2023
|
PRIMARY | |||
|
DB11189
Created by
admin on Fri Dec 15 15:51:00 GMT 2023 , Edited by admin on Fri Dec 15 15:51:00 GMT 2023
|
PRIMARY | |||
|
IFN18A4Y6B
Created by
admin on Fri Dec 15 15:51:00 GMT 2023 , Edited by admin on Fri Dec 15 15:51:00 GMT 2023
|
PRIMARY | |||
|
SUB20731
Created by
admin on Fri Dec 15 15:51:00 GMT 2023 , Edited by admin on Fri Dec 15 15:51:00 GMT 2023
|
PRIMARY | |||
|
CHEMBL2108424
Created by
admin on Fri Dec 15 15:51:00 GMT 2023 , Edited by admin on Fri Dec 15 15:51:00 GMT 2023
|
PRIMARY | |||
|
C1505
Created by
admin on Fri Dec 15 15:51:00 GMT 2023 , Edited by admin on Fri Dec 15 15:51:00 GMT 2023
|
CONCEPT | Dietary Supplement | ||
|
238-852-2
Created by
admin on Fri Dec 15 15:51:00 GMT 2023 , Edited by admin on Fri Dec 15 15:51:00 GMT 2023
|
PRIMARY | |||
|
84645
Created by
admin on Fri Dec 15 15:51:00 GMT 2023 , Edited by admin on Fri Dec 15 15:51:00 GMT 2023
|
PRIMARY | |||
|
14783-68-7
Created by
admin on Fri Dec 15 15:51:00 GMT 2023 , Edited by admin on Fri Dec 15 15:51:00 GMT 2023
|
PRIMARY | |||
|
DTXSID90163815
Created by
admin on Fri Dec 15 15:51:00 GMT 2023 , Edited by admin on Fri Dec 15 15:51:00 GMT 2023
|
PRIMARY | |||
|
Magnesium glycinate
Created by
admin on Fri Dec 15 15:51:00 GMT 2023 , Edited by admin on Fri Dec 15 15:51:00 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD